+ 2.38
+ 1.66%

Recent FDA Approvals

Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner

read more

Merck Announces Supply Agreement With U.S. Government For Molnupiravir Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate COVID-19

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482). read more

Ampio Pharmaceuticals Highlights Newly Integrated Data From 4 Previous Clinical Trials Of Osteoarthritis Of The Knee Program

ENGLEWOOD, CO, June 16, 2021 – Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly read more

Eli Lilly To Test Injectable Migraine Med Against Biohaven’s Oral Nurtec In Head-To-Head Study

read more

Seraph Research Institute Highlights Will Move Forward With First Stage Of Approval Process For HIV Candidate; Press Release Notes Proprietary Technology For Pre-Investigational New Drug Meeting Licensed To Enochian BioSciences

(NASDAQ:ENOB) – A promising cure for HIV is moving one step closer to FDA approval. The novel approach to treating HIV in humans using cell therapy, developed by Dr. Serhat Gumrukcu (Dr. Serhat), Director of read more

What is an FDA Calendar?

Biotech investing is risk-fraught, as stocks are at the mercy of several catalysts – most of which are make-or-break events, aka binary events. A prudent investment strategy is to make informed decisions, being in the know of when to expect these events, how these events will pan out and the potential stock reaction in the run-up to the event and post the event.

Benzinga’s FDA calendar is a meaningfully designed, user friendly, dynamically updated and simplistic investment tool that is a ‘must-have’ for those looking to make money from the volatility that is typic of trading in biotech stocks.

The calendar lists down all key catalysts that can materially impact stocks, including:

  • PDUFA dates, or in other words FDA decision dates
  • Filing schedules for regulatory applications such as new drug application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc
  • FDA decisions (approvals/complete response letter/delay)
  • According to special statuses for treatment options, including orphan drug designation, rare disease designation, accelerated approval, priority review etc.
  • FDA’s Advisory Committee, or Adcom, meetings
  • Review meetings with FDA (pre-investigational new drug application meetings, end-of-phase meetings, Type A, Type B and Type C meetings)
  • Decisions by overseas regulatory agencies
  • Clinical data readouts
  • Presentation of data at various scientific conferences.

The calendar allows data screening, based on company names or tickers, events, date-wise or based on a date range. They are designed to serve as a ‘one-stop shop’ for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development. 

What is a Catalyst?

A catalyst is any event/development that has the potential to swing the stock, usually in an appreciable way, in either direction, depending on how it materializes. 

Biotech Stock Movers

Regulatory actions and clinical readouts are stock-moving catalysts. The magnitude of the impact is usually disproportionate. Most clinical-stage biotechs, or companies which are yet to commercialize a product, do not generate revenues. The exceptions are those which may have out-licensed therapies-in-development to another company and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.

A promising outcome in a particular stage of drug development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.

Similarly, an unfavorable or a partially successful outcome could suggest all the investment the company may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.

PDUFA and Adcom events are binary events that have two outcomes, triggering moves in stock depending on which outcome materializes.

Want Real Time Gainers? Start a free 14 day trial


Session: Jun 17, 2021 4:00 pm – Jun 18, 2021 1:38 pm
Symbol Open Close Change Change % Volume
Buy GERN Stock – Go to SoFi GERN
1.41 1.90 0.49 34.51% 259.64M
Buy BPTS Stock – Go to SoFi BPTS
10.60 12.40 1.80 16.97% 15.06K
Buy PDSB Stock – Go to SoFi PDSB
PDS Biotechnology
9.95 11.60 1.65 16.62% 2.42M
Buy VERV Stock – Go to SoFi VERV
Verve Therapeutics
31.92 36.61 4.69 14.69% 66.11K
Buy TCON Stock – Go to SoFi TCON
TRACON Pharmaceuticals
6.59 7.25 0.66 9.93% 49.96K
Buy BTX Stock – Go to SoFi BTX
15.34 16.85 1.51 9.84% 3.28M
Buy CDXS Stock – Go to SoFi CDXS
19.64 21.57 1.93 9.82% 55.35K
Buy VLON Stock – Go to SoFi VLON
Vallon Pharmaceuticals
4.79 5.23 0.44 9.18% 17.87K
Buy CVAC Stock – Go to SoFi CVAC
57.83 62.89 5.06 8.74% 5.32M
Buy CRNX Stock – Go to SoFi CRNX
Crinetics Pharmaceuticals
19.28 20.82 1.54 7.98% 32.38K
Buy VIRX Stock – Go to SoFi VIRX
Viracta Therapeutics
12.04 12.94 0.90 7.47% 15.38K
Buy XTLB Stock – Go to SoFi XTLB
XTL Biopharmaceuticals
3.27 3.50 0.23 7.03% 17.84K
Buy NTEC Stock – Go to SoFi NTEC
Intec Pharma
4.50 4.77 0.27 5.99% 1.44M
Buy STRO Stock – Go to SoFi STRO
Sutro Biopharma
18.73 19.76 1.03 5.47% 35.55K
Buy BLCM Stock – Go to SoFi BLCM
Bellicum Pharmaceuticals
3.18 3.35 0.17 5.34% 19.88K
Buy ATOS Stock – Go to SoFi ATOS
Atossa Therapeutics
5.14 5.41 0.27 5.30% 8.26M
Buy TLC Stock – Go to SoFi TLC
Taiwan Liposome Co
6.18 6.49 0.31 4.93% 70.38K
Buy ANPC Stock – Go to SoFi ANPC
AnPac Bio-Medical Science
4.33 4.54 0.21 4.73% 41.02M
Buy MESO Stock – Go to SoFi MESO
8.33 8.72 0.39 4.68% 23.32K
Buy FNCH Stock – Go to SoFi FNCH
Finch Therapeutics Group
15.89 16.62 0.73 4.59% 66.93K


Session: Jun 17, 2021 4:00 pm – Jun 18, 2021 1:38 pm
Symbol Open Close Change Change % Volume
Buy ORPH Stock – Go to SoFi ORPH
14.56 7.54 -7.02 -48.22% 84.47M
Buy ATHA Stock – Go to SoFi ATHA
Athira Pharma
18.24 11.38 -6.86 -37.62% 24.89M
Buy ENTX Stock – Go to SoFi ENTX
Entera Bio
5.19 4.51 -0.68 -13.11% 74.63K
Buy KMPH Stock – Go to SoFi KMPH
15.47 13.51 -1.96 -12.69% 2.19M
Buy MTP Stock – Go to SoFi MTP
Midatech Pharma
2.95 2.58 -0.37 -12.55% 3.81M
Buy OLMA Stock – Go to SoFi OLMA
Olema Pharmaceuticals
27.61 24.24 -3.37 -12.21% 25.60K
Buy SNPX Stock – Go to SoFi SNPX
11.13 9.80 -1.33 -11.95% 54.97K
Buy PTIX Stock – Go to SoFi PTIX
Protagenic Therapeutics
3.37 3.02 -0.35 -10.40% 5.77M
Buy OPT Stock – Go to SoFi OPT
9.10 8.17 -0.93 -10.22% 11.35K
Buy KDNY Stock – Go to SoFi KDNY
Chinook Therapeutics
16.00 14.52 -1.49 -9.29% 93.84K
Buy CDXC Stock – Go to SoFi CDXC
9.99 9.10 -0.89 -8.91% 60.98K
Buy APOP Stock – Go to SoFi APOP
Cellect Biotechnology
4.15 3.80 -0.35 -8.44% 1.89M
Buy PIRS Stock – Go to SoFi PIRS
Pieris Pharmaceuticals
3.80 3.48 -0.32 -8.41% 2.78M
Buy AMTI Stock – Go to SoFi AMTI
Applied Molecular
44.53 41.04 -3.50 -7.85% 18.47K
Buy GRAY Stock – Go to SoFi GRAY
Graybug Vision
5.74 5.29 -0.45 -7.85% 1.41M
Buy PRTK Stock – Go to SoFi PRTK
Paratek Pharmaceuticals
8.14 7.56 -0.58 -7.13% 96.20K
Buy PRLD Stock – Go to SoFi PRLD
Prelude Therapeutics
32.36 30.29 -2.07 -6.40% 11.73K
Buy ALZN Stock – Go to SoFi ALZN
Alzamend Neuro
10.09 9.45 -0.64 -6.34% 12.25K
Buy IPA Stock – Go to SoFi IPA
ImmunoPrecise Antibodies
7.37 6.91 -0.46 -6.25% 31.40K
Buy SNGX Stock – Go to SoFi SNGX
1.20 1.13 -0.08 -6.25% 31.12K

Frequently Asked Questions

What is an FDA PDUFA date?

What is an FDA PDUFA date?

Prescription Drug User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an ‘approved’ decision, or a ‘complete response letter’ or a delay due to reasons specific to the company or extraneous to the company.

PDUFA was passed in the U.S. in 1992, which allows the FDA to collect fees from the sponsor company to fund the review process.

A CRL is issued by the FDA when it deems that the regulatory application is not complete in its current form. The deficiencies usually that lead to rejection could be the need for additional clinical studies to establish the efficacy and/or safety of the treatment option, problems with chemistry, manufacturing and controls, etc.

A delay in the review period may stem from the FDA needs additional time to review any additional data/information that may have been tabled subsequent to the submission of the regulatory application or the FDA’s inability to complete site inspections where the drug ingredients are being made etc.

The FDA may mention a specific date or a period (say Q1, Q2, Q3, Q4, first-half, second-half, the name of the month) as the timeline by which a decision will be given. If the FDA does not mention any timeline, the company may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn’t provide a timeline either, it is left to the investors to do the calculations.


How long does an FDA approval take?

How long does an FDA approval take?

A regulatory application (NDA, sNDA, BLA, sBLA, etc.) is usually accepted for standard review or priority review. A standard review will mean the FDA has to hand out its verdict within 10 months of filing the application. The review window for a priority review gets shortened to six months.

Once a company files for a regulatory application, the FDA takes up to 60 days to respond with an ‘accepted for review’ or ‘refuse-to-file’ decision.


How do you find FDA approvals?

How do you find FDA approvals?

A Catalysts Calendar is one way of tracking all the decisions in a single place. Usually, the FDA puts out a release and/or communicates to the company, which in turn will issue a press release.